Moderna is trading 102.38% up at $128.92 after its personalized mRNA cancer vaccine, developed with Merck, met the primary recurrence-free-survival endpoint in a Phase 3 melanoma trial.
- The treatment also achieved the key secondary endpoint, reducing distant metastasis versus Keytruda alone.
- The positive readout marks a major late-stage oncology milestone and is driving a broader biotech rally, with XBI up 3.73%.